$IFRX News

Raymond James Upgrades InflaRx to Strong Buy, Raises Price Target to $9

HC Wainwright & Co. Maintains Buy on InflaRx, Raises Price Target to $8

Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $4

InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript

InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases - Slideshow

InflaRx Prices Underwritten Offering of 75M Shares At $2.00 Per Share

InflaRx Announces That It Intends To Develop Izicopan, An Oral C5A Receptor Inhibitor, In Life-Threatening Kidney Disorder AAV

InflaRx Regains Nasdaq Compliance

Guggenheim Reiterates Buy on InflaRx, Maintains $14 Price Target

InflaRx Announces New In Vitro Findings Demonstrating That Izicopan Does Not Exhibit Time-Dependent Inhibition Of CYP3A4, Indicator For Risk For Ddis And Liver Toxicity

InflaRx Highlights Data From Phase 3 Study Of Vilobelimab In Pyoderma Gangrenosum At 2026 AAD Annual Meeting

Guggenheim Maintains Buy on InflaRx, Lowers Price Target to $14

InflaRx Q4 EPS $(0.17) Beats $(0.18) Estimate, Sales $(39.501K) Miss $230.000K Estimate

InflaRx shares are trading higher after the company announced an oral presentation on vilobelimab Phase 3 results in pyoderma gangrenosum.

InflaRx shares are trading higher after the company announced an oral presentation on vilobelimab Phase 3 results in pyoderma gangrenosum.

InflaRx Presents Oral Presentation At 2026 American Academy Of Dermatology Annual Meeting

InflaRx Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

InflaRx N.V. (IFRX) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Slideshow

InflaRx Plans Workforce Reduction, Targets Mid-2027 Cash Runway

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation